Literature DB >> 10854907

Retinoic acid negatively regulates neuropeptide Y expression in human neuroblastoma cells.

P Magni1, E Beretta, E Scaccianoce, M Motta.   

Abstract

Retinoids are involved in the regulation of development and differentiation in many tissues, including the nervous system, where they have been associated with some neurotransmitter systems. In the present study, we evaluated the effects of all-trans retinoic acid (RA) on the biosynthesis and secretion of neuropeptide Y (NPY), a widely expressed neuroregulatory peptide. The SH-SY5Y human neuroblastoma cell line has been used as the in vitro model system. Treatment with 10 microM RA induced a marked decrease in NPY gene expression after as little as 3-6 h of incubation and resulted in its almost complete suppression at 12-24 h and after a 6-day differentiating treatment. The NPY content in cell extracts and the NPY secreted and accumulated in the culture medium were also reduced by exposure to 10 microM RA at 12 and 24 h and at 6 days. Moreover, RA treatment for 6 days, but not for 24 h, resulted in a marked stimulation of proNPY processing to mature NPY. The presence of negative retinoic acid-response elements in the human NPY promoter (up to -1078 bp) was excluded by a computer search. When SH-SY5Y cells were treated simultaneously with 20 nM TPA and 10 microM RA for 24 h, the marked stimulatory effect of TPA alone was completely suppressed. These observations suggest that the expression of NPY in SH-SY5Y human neuroblastoma cells is negatively regulated by RA at the level of gene expression, probably by mechanisms involving the interaction of activated RARs with transcription factors (such as AP-1).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854907     DOI: 10.1016/s0028-3908(99)00231-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  Human cathepsin V protease participates in production of enkephalin and NPY neuropeptide neurotransmitters.

Authors:  Lydiane Funkelstein; W Douglas Lu; Britta Koch; Charles Mosier; Thomas Toneff; Laurent Taupenot; Daniel T O'Connor; Thomas Reinheckel; Christoph Peters; Vivian Hook
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

2.  Development of Neuropeptide Y and Cell-Penetrating Peptide MAP Adsorbed onto Lipid Nanoparticle Surface.

Authors:  Sara Silva; Joana Marto; Lídia M Gonçalves; Henrique S Fernandes; Sérgio F Sousa; António J Almeida; Nuno Vale
Journal:  Molecules       Date:  2022-04-24       Impact factor: 4.927

3.  Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Authors:  C Lu; L Everhart; J Tilan; L Kuo; C-C J Sun; R B Munivenkatappa; A-C Jönsson-Rylander; J Sun; A Kuan-Celarier; L Li; K Abe; Z Zukowska; J A Toretsky; J Kitlinska
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

4.  Fenretinide treatment prevents diet-induced obesity in association with major alterations in retinoid homeostatic gene expression in adipose, liver, and hypothalamus.

Authors:  George D Mcilroy; Mirela Delibegovic; Carl Owen; Patrick N Stoney; Kirsty D Shearer; Peter J McCaffery; Nimesh Mody
Journal:  Diabetes       Date:  2012-11-27       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.